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Abstract
Background: Non-adherence is one of the strongest predictors of therapeutic failure in HIV-positive patients.
Virologic failure with subsequent emergence of resistance reduces future treatment options and long-term clinical
success.
Methods: Prospective observational cohort study including patients starting new class of antiretroviral therapy (ART)
between 2003 and 2010. Participants were naïve to ART class and completed ≥1 adherence questionnaire prior to
resistance testing. Outcomes were development of any IAS-USA, class-specific, or M184V mutations. Associations
between adherence and resistance were estimated using logistic regression models stratified by ART class.
Results: Of 314 included individuals, 162 started NNRTI and 152 a PI/r regimen. Adherence was similar between
groups with 85% reporting adherence ≥95%. Number of new mutations increased with increasing non-adherence. In
NNRTI group, multivariable models indicated a significant linear association in odds of developing IAS-USA (odds
ratio (OR) 1.66, 95% confidence interval (CI): 1.04-2.67) or class-specific (OR 1.65, 95% CI: 1.00-2.70) mutations.
Levels of drug resistance were considerably lower in PI/r group and adherence was only significantly associated with
M184V mutations (OR 8.38, 95% CI: 1.26-55.70). Adherence was significantly associated with HIV RNA in PI/r but
not NNRTI regimens.
Conclusion: Therapies containing PI/r appear more forgiving to incomplete adherence compared with NNRTI
regimens, which allow higher levels of resistance, even with adherence above 95%. However, in failing PI/r regimens
good adherence may prevent accumulation of further resistance mutations and therefore help to preserve future drug
options. In contrast, adherence levels have little impact on NNRTI treatments once the first mutations have emerged.
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Introduction
Combined antiretroviral therapy (ART) aims at continuous
and lasting suppression of viral replication, which is one of the
most important factors influencing long-term prognosis of HIV-
infected individuals [1,2]. The importance of adherence to ART
has increased as treatment of HIV at present requires life-long
therapy once initiated. Non-adherence to therapy has been
shown to be one of the strongest predictors of failure of ART
[3,4]. Long-term viral suppression requires very high if not
perfect adherence, however recent studies have shown that
the majority of patients on potent current regimens are able to
maintain viral suppression at adherence rates lower than 95%
[5–8].
Virologic failure is associated with increased risk of
emergence of drug resistance [9] and therefore reduces future
treatment options and long-term clinical success [10,11].
Studies of the relationship between adherence and resistance
in HIV were only conducted a few years ago and indicate that
the relationship is more complicated than originally thought,
with each drug class having a unique adherence-resistance
relationship [12–17].
The adherence-resistance relationship in historic
monotherapy regimens containing a single unboosted protease
inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor
(NNRTI) is thought to be similar. Studies showed that most
drug resistance mutations were occurring in individuals with
adherence above 90% [10,18–20]. A subsequent mathematical
model of PI regimens determined that the maximal resistance
occurs at 87% adherence and declines only modestly with
perfect adherence [21]. This degree of adherence is low
enough to allow for viral failure while high enough to exert
selective pressure for resistant virus to emerge.
Ritonavir boosted PI regimens allow for more potent viral
suppression than ritonavir unboosted PIs and this reduces the
emergence of resistance mutations. Boosting increases the
half-life of the PI and so PI concentrations remain in a
suboptimal therapeutic range for a briefer time during periods
of non-adherence [18]. Resistance to PIs usually requires
multiple mutations and thus exhibit a high genetic barrier;
therefore high level resistance requires both ongoing viral
replication and sufficient drug exposure to create a selective
advantage for drug-resistant virus [22].
For NNRTIs, resistance is associated with interruptions in
therapy [23] and develops at a lower level of adherence than PI
resistance [24]. In addition it has been shown that minority
variants harbouring drug resistance mutations can jeopardize
therapeutic success of NNRTI but not boosted PI containing
regimens [25–27]. Unlike most PI drugs, resistance to the
NNRTIs nevirapine and efavirenz requires only a single
mutation at the K103N codon and even a single dose of NNRTI
monotherapy can result in resistance [28]. In addition, NNRTIs
have long half-lives allowing the virus to replicate in the
presence of low but detectable plasma levels in the case of
consecutive missed doses. Resistance mutations are common
in patients with any level of adherence that is insufficient for full
viral suppression but almost absent in highly adherent patients.
The clinical implications of NNRTI resistance are considerable
since NNRTI resistance almost universally confers cross-
resistance to first generation NNRTIs and drug resistance
mutations persist due to low fitness cost in most cases even
after drug discontinuation [29].
The potency of the ART regimen, defined as the likelihood to
suppress HIV-1 viremia below the limits of standard assay
detection for prolonged periods of time, is the largest single
determinant of the development of resistance for all ART
classes. The fitness cost of resistance and the genetic barrier
to resistance are important but they matter most during active
viral replication [13]. Therefore, complete viral suppression and
consequently optimized adherence are the undisputed goals of
therapy. Adherence patterns of individuals can also have public
health implications through the spread of drug-resistant strains
of HIV to uninfected or drug-naïve individuals, limiting their
future treatment options [30,31].
The goal of the study is to quantify the impact of adherence
to ART on the development of class-specific resistance
mutations in patients starting a new class of ART.
Methods
Ethics statement
Local ethical committees of all seven participating study sites
(Kantonale Ethikkommission Bern, Ethikkommission beider
Basel (EKBB), Ethikkommission des Kantons St. Gallen,
Kantonale Ethikkommission Zürich, Comitato etico cantonale
del Ticino, Commission d'éthique de la recherche clinique de la
faculté de biologie et de medicine de l'université de Lausanne,
Comité d'éthique du départment de médicine des hôpitaux
universitaires de Genève) have approved the study and written
consent has been obtained from all participants.
Selection of patients and genotypic drug resistance
tests
Patients for this study were selected from the SHCS, which
is a nationwide observational study of HIV infected individuals
in medical care in Switzerland. In semi-annual visits, laboratory
measurements are performed and clinical questionnaires are
administered [32]. The genotypic drug resistance data stem
from the SHCS drug resistance database, which is a central,
anonymized collection of all genotypic drug resistance tests
ever performed on SHCS enrolees by one of the four
authorized laboratories in Switzerland [16], complemented by a
systematic retrospective collection of pre-treatment genotypes
[33]. The data are stored in SmartGene’s Integrated Data
Network Services tool (Version 3.6.1).
The SHCS drug resistance database was screened for
genotypic drug resistance tests (GRT) which were performed
while patients were receiving ART and to which an adherence
assessment could be linked. In particular, GRTs/patients were
included if the following conditions were fulfilled (Figure 1):
Patients had to be either 1) therapy naïve individuals initiating
either a ritonavir-boosted PI (PI/r) or a NNRTI regimen or 2) if
having failed a first regimen with an on-treatment HIV RNA
>500 copies/mL after 24 weeks of therapy, they must have
initiated a second regimen with two fully active drugs
(corresponding to a Stanford genotypic sensitivity score < 2)
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that contained a different third drug class (i.e., NNRTI or PI/r)
than the initial regimen. Moreover, GRT included in the
analysis had to be performed after a minimum ART exposure
duration of 30 days, be linked to a completed adherence
questionnaire within 180 days of the genotype, and an HIV
RNA measurement must have been obtained on the same
treatment regimen. These conservative selection criteria were
designed to maximize sample size while only measuring newly
emerging drug resistance mutations against antiretroviral
therapies that were functional at the time of initiation. We
further aimed to exclude salvage therapies, because the origin
of mutations and consequently the impact of adherence can
often no longer be assessed accurately in this population.
Hence, GRTs performed on patients receiving integrase
inhibitors or CCR5 entry inhibitors were also excluded from this
analysis because in Switzerland these drugs were only used in
trials of salvage treatments during the observation period.
Adherence.  On twice-yearly study visits, levels of self-
reported adherence are assessed via interview with the
clinician. Patients are asked about the frequency of missed
drug doses over the past four weeks (never, less than once a
month, monthly, twice a month, weekly, more than once a
week, daily) and whether consecutive doses of ART were
missed. Using the first question plus the dosing frequency of
the regimen, the percentage adherence was calculated and
then categorized into 100%, 95-99%, and <95%. We
considered the inclusion of both adherence measures
(percentage adherence and consecutive missed doses)
together as well as separate in all models. The predictive value
of the adherence questions and non-adherence definitions with
regard to viral load levels have been demonstrated previously
[3].
Statistical analysis
The primary study outcome was the new emergence of any
International AIDS Society – USA drug resistance mutations
while receiving antiretroviral therapy [34]. The primary
explanatory variable of interest was adherence to antiretroviral
therapy over the past 6 months, stratified into the following
categories: 100%, 95-99%, and<95% adherence. In order to
test the independent association of adherence with emergence
of drug resistant mutations, multivariable models were
constructed adjusting for the following pre-specified potential
confounders: age, gender, active or prior injecting drug use,
AIDS-defining events, baseline CD4 cell count, baseline HIV-1
RNA, and the nucleoside reverse transcriptase inhibitor (NRTI)
backbone combination (in particular the inclusion of 3TC, a low
genetic barrier drug) and number of previous regimens.
Univariable and multivariable logistic regression models were
performed separately for NNRTI and PI/r. Unless a significant
departure from linearity was detected by likelihood ratio tests,
levels of adherence were primarily fitted as linear trends across
the pre-defined strata.
In addition to the analysis of any new IAS-USA mutations,
further sub-analyses considered specific types of mutations,
which were any major mutations to the group-specific third
drugs (i.e. either PI/r or NNRTI) and the new emergence of
M184V mutations. The latter mutation was selected due to its
low genetic barrier and the widespread use of M184V selecting
drugs in Switzerland. These sub-analyses were restricted to
individuals with the appropriate drug exposures, which selected
for the mutations of interest. As a secondary outcome, we
compared levels of plasma HIV RNA around the time of the
adherence assessment across the different strata of
medication adherence.
Because a number of included patients lacked information
from prior genotypic drug resistance testing (Table 1) we
performed sensitivity analyses by repeating our analyses on
the subset of individuals who either received their first ART
ever or those who started a new line of ART (including one new
drug class) and who had a prior on-treatment genotypic
resistance test done.
All analyses were done using SAS v9.2 (SAS Corporation,
Cary, NC, USA) and Stata v12.0 (StataCorp LP, College
Station, TX, USA). All p-values are two-sided and the threshold
for statistical significance was set at 0.05.
Results
Patient Characteristics
Of over 6700 GRT from therapy-exposed individuals, we
were able to select 314 test results belonging to 162 individuals
receiving NNRTI and 152 receiving PI/r (Figure 1). Patient
characteristics are displayed in Table 1. In the NNRTI group,
72% of all individuals received efavirenz (EFV), 27% nevirapine
(NVP) and 1% etravirine. The most frequent PI used in the PI/r
group was lopinavir (55%), followed by atazanavir (39%). The
nucleoside reverse transcriptase inhibitor backbones contained
either lamivudine (3TC) or emtricitabine (FTC) in 90% (PI/r)
and 84% (NNRTI) of individuals, thymidine analogues in 30%
(PI/r) and 46% (NNRTI), tenofovir (TDF) in 53% (PI/r) and 44%
(NNRTI), and abacavir (ABC) in 18% (PI/r) and 14% (NNRTI)
of all regimens.
Among the most notable differences between the two groups
were the somewhat higher proportion of individuals who have
acquired HIV via injecting drug use in the PI/r group and the
lower proportion of individuals in the PI/r group who had
previously experienced virological failure on antiretroviral
therapy. Levels of adherence were similar between the PI/r and
NNRTI groups, and approximately 85% of individuals reported
adherence levels >95% in both groups. Due to the limited
number of cases, all adherence strata <95% were collapsed
into one group for further analyses.
Genotypic sensitivity score
As shown in table 2, levels of drug resistance were
considerably lower in the group of PI/r recipients – for example,
resistance to any IAS-USA mutations was detected in 56
(34.6%) of NNRTI recipients versus 14 (9.2%) of PI/r recipients
(p<0.001). These findings were confirmed by sensitivity
analyses (Table S1).
Indeed, the Stanford cumulative genotypic sensitivity scores
of the drug combination at the time of genotyping (i.e. the
number of active drugs) were generally higher in the PI/r group
(median [IQR], 3 [3–3]) than in the NNRTI group (2 [1-3],
Adherence and Development of HIV Resistance
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Figure 1.  Selection of genotypic drug resistance tests.  
doi: 10.1371/journal.pone.0077691.g001
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Wilcoxon rank sum p<0.001; data not shown). Results for the
sensitivity analysis were identical (data not shown).
Moreover, when comparing cumulative genotypic sensitivity
scores upon failure across adherence strata, there was a trend
for lower scores (i.e. more resistance) with lower adherence in
the PI/r group (reduction of -0.09 [-0.20; 0.01] score points with
decreasing adherence, p=0.074, data not shown). No such
trend was observed for the NNRTI group. Potentially those
results in the PI/r group could have been influenced by
previous virological failures, which may have affected
genotypic sensitivity scores for NRTI drugs (not PI/r or NNRTI
scores, however). Nevertheless, those associations between
GSS and adherence in the PI/r were still observed when
repeating the analysis on the set of individuals starting their
first antiretroviral therapy (-0.17 [-0.30; -0.03], p=0.016; data
not shown).
Associations of emergence of drug resistance with
adherence
Descriptive analyses shown in Table 2 indicate that
adherence may indeed influence the probability of detecting
IAS-USA mutations by genotypic testing. In the group of NNRTI
recipients there was a steady increase in the proportion of tests
with resistance mutations for all three outcomes - the presence
of any mutations, NNRTI mutations, or M184V mutation. This
trend persisted even in an analysis of adherence categorized
into the five original strata (not shown). Increases in
proportions of resistant viruses with lower adherence levels
Table 1. Baseline characteristics of population by drug class.
Variables Category PI/r NNRTI
N (%)  152 (100.0) 162 (100.0)
Female – n(%)  46 (30.3) 41 (25.3)
Age, median [IQR]  40 [35 to 46] 39 [33 to 46]
Ethnicity – n(%) White 112 (73.7) 110 (67.9)
 Black 27 (17.8) 39 (24.1)
 Other 13 (8.6) 13 (8.0)
Mode of HIV acquisition – n(%) Heterosexual 61 (40.1) 86 (53.1)
 Intravenous drug use 24 (15.8) 11 (6.8)
 Homosexual 65 (42.8) 59 (36.4)
 Other 2 (1.3) 6 (3.7)
Previous or current IDU – n(%)  26 (17.1) 12 (7.4)
Year of ART initiation, median [IQR]  2003 [2000 to 2006] 2002 [1999 to 2005]
Baseline CD4, n, median [IQR]  140; 218 [101 to 360] 158; 190 [78 to 307]
Baseline HIV RNA, n, median [IQR]  138; 5.1 [4.8 to 5.7] 150; 5.1 [4.6 to 5.7]
Ever virologically failed ART  2 (1.3) 22 (13.6)
Ever failed 3TC  0 (0.0) 18 (11.1)
Ever failed other NRTI  2 (1.3) 22 (13.6)
Ever failed PI  0 (0.0) 20 (12.3)
Ever failed AZT or d4T  1 (0.7) 22 (13.6)
Number of previous lines of ART- n(%) 0 (First line treatment) 45 (29.6) 57 (35.2)
 1 47 (30.9) 44 (27.2)
 2 25 (16.4) 21 (13.0)
 3 22 (14.5) 19 (11.7)
 4 5 (3.3) 11 (6.8)
 5 or more 8 (5.3) 10 (6.2)
Prior RT- n(%) Results available 114 (75.0) 98 (60.5)
 With GSS >2.5 at baseline 112 (98.3) 95 (96.9)
Time between adherence assessment and genotypic testing, median number of days, [IQR]  0 [-8.5 to 19] 0 [-11 to 34]
Adherence - n (%) 100% 113 (74.3) 108 (66.7)
 95%-99% 18 (11.8) 28 (17.3)
 90%-94% 15 (9.9) 18 (11.1)
 85%-89% 1 (0.7) 3 (1.9)
 <85% 5 (3.3) 5 (3.1)
HIV RNA at genotypic test, median [IQR]  2.7 [2.3 to 3.8] 3.5 [2.9 to 4.6]
CD4 cell count at genotypic test, n, median [IQR]  124; 351 [238 to 494] 136; 377 [215 to 553]
IQR=interquartile range, IDU=injecting drug use, ART=antiretroviral therapy, NNRTI= non-nucleoside reverse transcriptase inhibitor, PI/r=ritonavir-boosted protease
inhibitors, NRTI= nucleoside reverse transcriptase inhibitor, 3TC= lamivudine, AZT=zidovudine, d4T=stavudine, RT=resistance test, GSS=genotypic sensitivity score
doi: 10.1371/journal.pone.0077691.t001
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were observable when analysing any IAS-USA mutations or
M184V as outcomes, but not with the emergence of PI
mutations. However, when performing sensitivity analyses with
a more strictly defined population who either had started their
first ART or with a prior on-treatment GRT available(Table S1)
those associations of adherence levels with emergence of new
NNRTI or M184V mutations were no longer apparent, possibly
owing to the lower sample size.
Kaplan-Meier curves for the unadjusted association between
adherence and development of mutations were estimated
(Figure 2). These observed adherence-resistance relations
were further tested for statistical significance in univariable and
multivariable logistic regression models. In univariable
analyses, the only outcome showing a statistically significant
association with adherence in the PI/r group was the
emergence of the M184V mutation (n=137 patients on 3TC or
FTC backbone, odds ratio [95% confidence interval]: 4.98
[1.41-17.62]) per increase in adherence stratum (Table 3). This
estimate should be interpreted with caution, however, because
the M184V mutations did not occur in the middle adherence
stratum. In multivariable models, adherence was still
significantly associated with development of a new M184V
mutation (8.38 [1.26-55.70], p=0.03), however the confidence
intervals are very wide and reflected the small sample size of
this subgroup.
In the NNRTI group, only the development of any IAS-USA
mutations showed a statistically significant linear univariable
association with adherence (1.61 [1.06-2.46]). The association
between NNRTI mutations (1.46 [0.94-2.23]) and M184V (1.01
[0.49-2.08]) and adherence did not reach statistical
significance. In multivariable models provided in Table 4, the
emergence of any IAS-USA mutation remains significantly
associated with adherence (1.66 [1.04-2.67]). In addition, the
association between adherence and NNRTI mutations
becomes significant after adjustment for confounders (1.65
[1.00-2.70]). In multivariable models for any IAS-USA mutation
and NNRTI mutation, currently being on a regimen with ABC,
TDF or didanosine (ddI) resulted in a decreased risk for the
development of mutations. The majority of those treatments
contained TDF (143 of 204, 70%), which is more potent, can be
given once daily, is better tolerated than zidovudine (AZT) [35],
and hence may have led to fewer problems with adherence
and less drug resistance [36].
Associations of HIV RNA and adherence
We further investigated the impact of adherence on levels of
HIV RNA measured at time of genotypic testing in our sample.
In the PI/r group, average levels of HIV RNA log10 copies/mL
(standard deviation) were increasing with lower adherence and
reached 2.8 (1.5) log copies/mL in the 100% adherence group,
3.2 (1.5) log copies/mL in the 95-99% group and 3.7 (0.9) log
copies/mL in the <95% group. Consequently, there was a
statistically significant linear trend of 0.5 [95% confidence
interval 0.1-0.8] log10 copies/mL per lower adherence stratum
(R2=0.053; F-test p=0.004). No such relationship was observed
in the NNRTI group, where HIV RNA levels remained
approximately constant across all adherence strata (in
descending order) with 3.6 (1.3), 3.6 (0.9), and 4.0 (0.9) log10
copies/mL. Neither of these adherence group means differed
significantly (F-test p=0.33). The sensitivity analysis yielded
almost identical results. For the PI/r group a decrease in
adherence was associated with a 0.46 [95% confidence
interval 0.1-0.8] log10 copies/mL increase in HIV RNA, whereas
no association was observed for the NNRTI group.
Durability of regimens
We compared the durability of the regimens and found the
viral failure rate to be significantly higher in those on NNRTI
compared to PI (78.0% vs. 47.2%, p<0.001). In those who
experienced virological failure, the average durability of the
regimen was 21 and 15 months in NNRTI and PI/r respectively
(p=0.039) Within the NNRTI group, the average durability of
those on regimens with EFV was slightly longer than those on
NVP (22 versus 19 months) but the difference was not
statistically significant.
Table 2. Development of new mutation by adherence level and drug class.
 Adherence Level PI/r NNRTI
Any IAS-USA mutation
100% 10/113 (8.9) 31/108 (28.7)
95-99% 1/18 (5.6) 12/28 (42.9)
<95% 3/21 (14.3) 13/26 (50)
Any mutation against group-specific drug (PI/r or NNRTI)
100% 3/113 (2.7) 27/108 (25)
95-99% 1/18 (5.69) 8/28 (28.6)
<95% 0/21 (0.0) 11/26 (42.3)
New emergence of M184V/I
100% 1/106 (1.0) 13/86 (15.1)
95-99% 0/13 (0.0) 5/24 (20.8)
<95% 3/18 (16.6) 5/22 (22.7)
NNRTI= non-nucleoside reverse transcriptase inhibitor, PI/r=ritonavir-boosted protease inhibitors
doi: 10.1371/journal.pone.0077691.t002
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Discussion
In this carefully selected data set of genotypic drug
resistance tests and adherence measurements from individuals
treated with potent combination antiretroviral therapies, we
observed associations of NNRTI drug resistance emergence
with levels of prior self- reported adherence, while associations
for PI/r regimens varied according to type of resistance
mutation. Therapies containing boosted PI seemed more
forgiving to incomplete compliance compared with NNRTI-
based therapies, which allowed much higher levels of
resistance emergence, even at adherence levels of 95% and
higher. In the NNRTI group, levels of resistance defined by the
presence of at least one IAS-USA mutation increased markedly
from the highest (29%) to the lowest adherence stratum (50%).
Not surprisingly, many of those individuals from the NNRTI
group with at least 1 new mutation also harboured NNRTI
resistant viruses (ranging from 83% - 87%, Table 2), which
Figure 2.  Kaplan-Meier curves for the association of adherence on the development of new resistance mutations.  The left
column is those on PI/r regimens (N=152) and the right column is those on NNRTI regimens (N=162).
doi: 10.1371/journal.pone.0077691.g002
Table 3. Multivariable logistic regression models for the development of mutations in individuals on PI/r regimens.
Variable Any IAS-USA mutation Any PI/r mutation Any M184V/I mutation*
 Multivariable OR p-value Multivariable OR p-value Multivariable OR p-value
Female 0.94 (0.25 - 3.55) 0.92 2.01 (0.19 - 20.69) 0.56 0.45 (0.03 - 6.69) 0.57
Age - per 10 years 0.88 (0.45 - 1.75) 0.72 0.74 (0.19 - 2.88) 0.66 0.55 (0.10 - 2.95) 0.48
Previous or current IDU 1.87 (0.49 - 7.19) 0.36 2.07 (0.15 - 28.82) 0.59 3.14 (0.26 - 37.46) 0.37
AIDS 1.60 (0.44 - 5.79) 0.48 0.83 (0.06 - 11.37) 0.89 2.94 (0.23 - 37.30) 0.41
Baseline sqrt CD4 0.99 (0.89 - 1.09) 0.84 1.02 (0.84 - 1.23) 0.85 0.87 (0.66 - 1.14) 0.30
Baseline log HIV-1 RNA 0.79 (0.04 - 16.01) 0.88 0.92 (0.02- 53.13) 0.97 0.03 (0.00 - 36.86) 0.34
AZT or d4T backbone 1.79 (0.52- 6.13) 0.35 1.76 (0.19- 15.91) 0.61 9.75 (0.34- 276.9) 0.18
Adherence (per increase in stratum) 1.23 (0.57 - 2.65) 0.59 0.65 (0.11 - 3.73) 0.63 8.38 (1.26 - 55.70) 0.03
*. Including only those patients on a regimen with a 3TC or FTC backbone (n=137)
OR=odds ratio, IDU=injecting drug use, PI/r=ritonavir-boosted protease inhibitors, NRTI= nucleoside reverse transcriptase inhibitor, AZT=zidovudine, d4T=stavudine OR:
odds ratio; IDU: injecting drug use; AZT: zidovudine
doi: 10.1371/journal.pone.0077691.t003
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reflects the fact that NNRTI resistance mutations tend to
require few nucleotide changes, incur a small fitness cost on
the virus, and have a large resistance impact when compared
with PI mutations. For example, 48% to 64% of new NNRTI
mutations consisted of the amino acid change K103N (data not
shown), which is known to emerge rapidly and to confer full
resistance to EFV and NVP. In contrast, there was little
statistical evidence for increases in resistance levels at lower
adherence strata when a boosted PI was used, although these
analyses were somewhat limited in power due to the low
frequency of resistance emergence on boosted PI regimens in
general.
Further noteworthy, we found associations of HIV RNA levels
with adherence strata in the PI/r group, but not in the NNRTI
group. Most likely, this observation is tied to the fact that a
single NNRTI mutation can render NNRTI-drugs like efavirenz
or nevirapine impotent, whereas several mutations are usually
required to have a strong impact on PI susceptibility. Therefore,
this similarity in HIV RNA levels across adherence strata in the
NNRTI group possibly reflects the higher degree of resistance
in NNRTI regimens and consequently the lower residual
efficacy of those treatments. This notion is supported by the
finding that the Stanford cumulative genotypic sensitivity scores
of the drug combination at the time of genotyping were
generally higher in the PI/r group than in the NNRTI group and
that there was a trend for lower scores (i.e. more resistance)
with lower adherence in the PI/r group but not in the NNRTI
group.
Taken together, these observations suggest that good
adherence may be beneficial even with virologically failing PI/r
regimens, because this may prevent the accumulation of
further resistance mutations and can therefore help to preserve
future drug options. In contrast, adherence levels seem to have
little impact on NNRTI treatments once the first mutations, and
NNRTI mutations in particular, have emerged [37].
Our data are largely consistent with previous studies
showing that antiretroviral classes may have different
adherence–resistance relationships. Gallego et al [38] found
resistance in PIs was limited to individuals reporting more than
90% adherence. Parienti et al. found that NNRTI resistance is
associated with interruptions of therapy [22]. Sethi et al. [23]
and Maggiolo et al [14] found resistance occurring in those on
NNRTIs at lower levels of adherence than that observed in
patients who develop resistance to PIs. Longitudinal studies by
Bangsberg et al. and Miller et al. found that increasing
adherence independently predicts the rate of accumulation of
drug resistance mutations among patients with persistent
detectable viraemia [10,39]. Collectively, these studies have
shown that the greatest risk for resistance is in patients with
high levels of adherence and incomplete viral suppression, and
this relationship is strongest for PI-based therapy. Our
analyses complement previous work by additionally
considering the impact of adherence on HIV RNA levels and
genotypic sensitivity scores upon virological failure. The
importance of viral replication on HIV-related, but not AIDS-
defining morbidities has been demonstrated previously [40],
and our data suggest that improved adherence on failing PI/r
regimens may still contribute to partial viral control, but not with
failing NNRTI treatments.
Several limitations should be noted about this analysis.
Despite drawing from large observational databases including
almost 6800 genotypic drug resistance tests from drug
exposed individuals, the final numbers of patients included in
this analysis were small, but of the same order of magnitude of
other studies [6,14,15]. Owing to the observational nature of
this study, the treatments received were not randomized and
the collection of genotypic data was not strictly enforced by
study protocols. Moreover, we did not strictly analyze GRTs
from first-line failures, but included additional data to increase
sample size (Figure 1). We can therefore not exclude residual
confounding in our analyses Furthermore, our adherence
assessments are based on self-report, which is prone to
recollection biases or over-reporting. Although we ask about
consecutive missed doses, self-report data may not be
sensitive to important adherence patterns, such as treatment
interruptions. Moreover, not all individuals had genotypic
resistance data collected prior to treatment initiation or at time
of the first virological failure available, and some mutations
Table 4. Multivariable logistic regression models for the development of mutations in individuals on NNRTI regimens.
Variable  Any IAS-USA mutation Any NNRTI mutation Any M184V/I mutation
  Multivariable OR p-value Multivariable OR p-value Multivariable OR p-value
Female  1.63 (0.70 - 3.78) 0.26 1.17 (0.48 - 2.85) 0.72 2.22 (0.76 - 6.51) 0.15
Age - per 10 years  0.76 (0.50 - 1.15) 0.19 0.79 (0.50 - 1.23) 0.30 0.97 (0.56 - 1.71) 0.93
Previous or current IDU  0.46 (0.09 - 2.43) 0.36 0.56 (0.11 - 3.08) 0.52 1.85 (0.29 - 11.79) 0.52
AIDS  0.83 (0.36 - 1.95) 0.68 0.78 (0.32 - 1.94) 0.62 0.98 (0.31 - 3.13) 0.98
Baseline sqrt CD4  0.96 (0.91 - 1.03) 0.28 0.94 (0.87 - 1.01) 0.07 0.95 (0.87 - 1.04) 0.29
Baseline log HIV-1 RNA  0.71 (0.17 - 2.91) 0.63 0.86 (0.17 - 4.21) 0.85 0.84 (0.07 - 9.51) 0.89
NRTI backbone 3TC or FTC 0.36 (0.10 - 1.29) 0.12 0.26 (0.07 - 1.00) 0.05 1.53 (0.10 - 23.81) 0.76
 AZT or d4T 0.51 (0.16- 1.67) 0.27 0.39 (0.11- 1.36) 0.14 2.31 (0.37- 14.49) 0.37
 ABC TDF or ddI 0.19 (0.05 - 0.68) 0.01 0.13 (0.03 - 0.53) 0.004 0.23 (0.03 - 1.85) 0.17
Adherence (per increase in stratum)  1.66 (1.04 - 2.67) 0.03 1.65 (1.00 - 2.70) 0.05 1.47 (0.79 - 2.76) 0.23
OR=odds ratio, IDU=injecting drug use, NNRTI= non-nucleoside reverse transcriptase inhibitor , NRTI= nucleoside reverse transcriptase inhibitor, 3TC= lamivudine,
FTC=emtricitabine, AZT=zidovudine, d4T=stavudine, ABC=abacavir, TDF=tenofovir, ddI=didanosine
doi: 10.1371/journal.pone.0077691.t004
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could potentially have been transmitted. However, extensive
longitudinal assessments of transmitted drug resistance in
Switzerland have shown that the presence of drug resistance
mutations before therapy initiation is still relatively rare [41].
Our observations have important clinical implications. It is
self-evident that good adherence promotes viral suppression
and reduces the emergence of resistance mutations. In this
analysis, we also observed evidence that adherence levels
influenced resistance levels of virologically failing or failed PI/r
regimens. Thus, even when partial resistance has occurred,
good adherence levels may slow down or even stop
progression to higher resistance levels, thereby possibly
extending the durability of PI/r regimens [37]. This effect may
have great relevance in settings of limited antiretroviral drug
availability and virological monitoring. In contrast, current
WHO-recommended first-line treatments are based on NNRTI
for cost reasons, which must be considered sub-optimal from
the standpoint of emergence of resistance. In NNRTI therapies,
resistance emergence is more likely with incomplete drug
intake and cannot be limited by improved adherence later on.
Thus, even temporary slips in adherence carry a substantial
risk for losing the full drug combination to resistance.
In summary, our data suggest that promoting adherence may
still be worthwhile for individuals receiving virologically failing
PI/r regimens for damage control, but failing NNRTI regimens
should be switched immediately.
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